Senior Study Director

• 2022 - Present

In a pivotal scientific leadership position as a Subject Matter Expert (SME), accountable for harmonizing global clients' needs, industry, commercial teams, and operations to consistently deliver top-tier services. The objective is to foster business expansion, elevate brand visibility, and reinforce alignment with core competencies, particularly in the fields of oncology and translational biology. In a pivotal scientific leadership position as a Subject Matter Expert (SME), accountable for harmonizing global clients' needs, industry, commercial teams, and operations to consistently deliver top-tier services. The objective is to foster business expansion, elevate brand visibility, and reinforce alignment with core competencies, particularly in the fields of oncology and translational biology.

Consultant

• 2020 - 2022

Principal Investigator / Program Director

• 2016 - 2020

Secured funding for IND-enabling studies and led federally funded initiatives, primarily centered on precision therapeutics for radiation-induced stress proteins in solid tumors. Directed collaborative efforts within a multidisciplinary team to identify, validate, and develop new pipeline targets. Managed various research methodologies, including in vitro and in vivo studies. Instrumental in fostering strategic partnerships, raising capital, and connecting with academia, industry, and the innovation ecosystem to facilitate valuable collaborations. Show less

Scientific Director

• 2019 - 2021

Managed biotech operations, including in-vitro and in-vivo studies, overseeing Operations, Supply Chain, Compliance, Procurement, and Budget Oversight. As MiM's program director, led IND enabling studies for mitofusin agonists for neuromuscular disease treatments. Managed post-execution activities, resource allocation, and research progress tracking. Facilitated collaboration among biotech, 15+ CROs, and the academic founder's lab, contributing to a $3 million capital raise. Prepared pre-clinical data packages covering biophysical characterization, indication prioritization, pharmacokinetics, biodistribution, efficacy relationships, testing strategies, and safety/toxicology studies. Show less

Visiting Scholar

• 2016 - 2020

Consultant

• 2012 - 2016

Performed strategic and risk analysis to aid early-stage biotech companies in pivoting and raising capital, while also reviewing and developing business and commercialization plans for biotech and medical device startups. Additionally, evaluated the feasibility of over 20 inventions, including patent assessment and freedom-to-operate (FTO) analysis. Performed strategic and risk analysis to aid early-stage biotech companies in pivoting and raising capital, while also reviewing and developing business and commercialization plans for biotech and medical device startups. Additionally, evaluated the feasibility of over 20 inventions, including patent assessment and freedom-to-operate (FTO) analysis.

Post Doc. Research Associate

• 2011 - 2015

Implemented OMICs approaches for biomarker and translational studies, including dataset analysis, and conducted in vivo Positron Emission Tomography (PET) imaging to measure FA oxidation. Additionally, assessed [11C] and [18F] Dihydroethidium (DHE) analogs as PET probes for reactive oxygen species. Implemented OMICs approaches for biomarker and translational studies, including dataset analysis, and conducted in vivo Positron Emission Tomography (PET) imaging to measure FA oxidation. Additionally, assessed [11C] and [18F] Dihydroethidium (DHE) analogs as PET probes for reactive oxygen species.